admin Cancer care treatments, including surgery, chemotherapy, and radiation, often come with harsh side effects that significantly impact patients’ quality of life. These traditional treatments, while effective, can lead to debilitating pain, fatigue, nausea, and a host of other physical and emotional challenges. The toll on patients and their families is immense, as they navigate the complexities of managing the disease alongside these adverse effects. Pain and suffering in oncology therapy remains a critical concern, as many treatments can cause severe and lasting discomfort, sometimes necessitating additional interventions that further burden the patient. Recognising these challenges, ChemoTech has developed a revolutionary technology, IQwave™-TSE – (Tumor Specific Electroporation) System, not only to be more efficient when other therapy fails but also designed to minimise pain and side-effects and improve the overall treatment experience. This innovative approach works in harmony with the body’s natural processes, offering a gentler, yet highly effective, alternative to conventional cancer therapies. Based at Medicon Village in Lund, Sweden, this Scandinavian company is committed to transforming oncology care with its unique and patented methods, ensuring that patients receive the most effective and gentle treatments available.
ChemoTech’s foundation is built on extensive experience in surgical oncology and clinical development. The company is dedicated to advancing cancer care through genuine research and clinical trials, leveraging its unique patented technology to develop innovative solutions. ChemoTech’s flagship product, the IQwave™ system, exemplifies this commitment by offering a powerful and effective treatment option for various cancer indications.
Fulfilling A Noble Mission
ChemoTech is dedicated to clinical development and scientific excellence, aspiring to revolutionise cancer care and pain management. Chemotech’s mission is to be a force in the development of technologies that improves clinical and health-economics for the global cancer market, and become the central and sensitizing therapy for Standard of Care in cancer for humans and animals. ChemoTech envisions developing tomorrow’s therapies and also making them accessible to patients who lack other treatment options due to financial or medical constraints or severe side effects. Their strategy involves enhancing their technology to be more effective, user-friendly, and adaptable to various clinical environments. Believing in combining solid scientific foundations with cost-efficiency, ChemoTech aims to offer cancer treatments and pain management that are accessible to all who need them. By focusing on the global cancer epidemic, they strive to adapt their unique methods to excel both clinically and financially, especially in regions with limited access to modern cancer treatments, while also developing solutions for conditions where existing therapies often fail or cause significant suffering.
The Visionary Leadership of Mohan Frick
‘Our mission at ChemoTech is to change the paradigm in cancer care by deliver cost-efficient, effective cancer treatments that significantly enhance patients’ quality of life’
– Mohan Frick
At the helm of ChemoTech is Mohan Frick, a visionary leader with over 30 years of experience in the medical technology sector. Frick’s journey began as a trainee at Getinge’s headquarters in Rochester, NY, where he quickly rose through the ranks to oversee global marketing and communication for ARJO, a subsidiary operating in over 20 countries. His early career was marked by significant achievements, including serving on ARJO’s global management team located inLuxembourg by the age of 27.
Frick’s diverse career path has seen him excel in various roles, including as a wealth manager and investment advisor with a focus on life sciences. His return to the medical field in 2012, specifically in oncology, set the stage for the development of ChemoTech’s innovative approach to cancer treatment. Collaborating his ideas with Professor emeritus Bertil Persson’s pre-clinical research, Frick and Persson pioneered TSE, a non-destructive cancer therapy that leverages electrical stimulations to induce cellular reactions and eliminate cancer cells through apoptosis. This method significantly reduces trauma for patients, aligning with ChemoTech’s mission to provide more humane and effective cancer treatments.
Tumour-Specific Electroporation: A Paradigm Shift in Oncology
The cornerstone of ChemoTech’s innovation is Tumour-Specific Electroporation (TSE), a technology that represents a significant advancement in cancer therapy. TSE utilises a patented and tumour adapted electrical impulses that widens the natural channels in the plasma membranes of cancer cells, enhancing the uptake of chemotherapeutic drugs. This method not only increases the efficacy of the drugs exponentially, but also minimises the physical trauma typically associated with other cancer treatments.
The IQwave 3.0 CE is a CE-marked medical device and its effectiveness is evidenced by its success in treating over 400 patients across South East Asia, India, Africa, and Ukraine. This groundbreaking technology has the potential to become a new paradigm in oncology care, offering a viable alternative to traditional treatments like surgery, radiation, chemotherapy and Immunotherapy. TSE’s ability to treat even non-responsive tumours and tumours in sensitive locations further underscores its revolutionary impact on cancer therapy.
Products and Applications
ChemoTech’s IQwave™ system, based on TSE technology, has been used to treat a range of cancers, including head and neck squamous cell carcinoma, malignant melanoma, basal cell carcinoma, adenocarcinoma of the breast and salivary gland, hypernephroma, Kaposi sarcoma, and transitional cell carcinoma. The system’s ability to enhance the effects of the treatments and create a powerful immunotherapeutic effect positions it as a leading solution in both palliative and curative care. An immunotherapeutic response is the body’s immune system being activated or enhanced to specifically target and destroy harmful cells, such as cancer cells, as part of a treatment. This response leverages the body’s natural defences to fight disease more effectively.
The IQwave™ system’s multi-directional electric fields improve current coverage throughout the treated tissue, offering unique capabilities for treating tumours in hard-to-reach places. With its portability and ease of use, the IQwave™ system is designed to be both efficient and effective, providing significant benefits to patients and healthcare providers alike.
Leveraging AI and Machine Learning for Enhanced Outcomes
‘Our groundbreaking TSE technology works in harmony with the body’s processes, minimising physical compromise while delivering highly effective cancer treatment’
– Robin Sukhia Chair of the Board of Directors
ChemoTech’s TSE technology and dynamic features are designed to include integration of artificial intelligence (AI) and machine learning into its health-tech solutions in the next coming versions. TSE’s dynamic features automatically adapt energy levels based on data on how the tumour behaves during the treatments, improving the precision and effectiveness of the therapy. However, even from a technology standpoint it is fairly easy to integrate AI to the IQwave and vetIQure Systems. The problem arises with obtaining certifications for these advanced functionalities from regulatory authorities in the EU, USA, and India. This remains a challenge. Despite these hurdles, ChemoTech continues to push the boundaries of innovation through ongoing research and development.
Measuring Success and Ensuring Safety
ChemoTech employs rigorous Post Market Surveillance (PMS) programs and clinical trials to measure the success and effectiveness of its health-tech solutions. By continuously documenting and publishing clinical achievements, the company ensures that its technologies meet the highest standards of safety and efficacy. ChemoTech’s commitment to patient and user safety is further reinforced by its compliance with CE Mark regulations, which mandate strict adherence to data privacy and security standards.
Overcoming Challenges and Expanding Reach
One of the biggest challenges ChemoTech has faced is securing collaborations with university hospitals in Sweden for clinical development. The Scandinavian market is relatively small, and the hurdle to establish partnerships for clinical trials is a well-known challenge. Despite these obstacles, ChemoTech remains determined to expand its reach and establish itself as a leader in oncology care by continue to establish international partnerships.
User-Friendly Technology for Healthcare Professionals and Patients
ChemoTech places a strong emphasis on developing user-friendly technologies that cater to both healthcare professionals and patients. The IQwave™ system, which supports TSE, is designed to be portable and easy to use, with treatment cycles lasting only 15-25 minutes. This efficiency, coupled with the system’s ability to perform under local anaesthesia and light sedation, makes it a preferred choice for both palliative and curative treatments.
Targeting Key Market Segments
ChemoTech’s TSE technology has the potential to revolutionise multiple market segments within oncology care. By offering a less destructive and more immune-responsive treatment option, TSE can complement existing therapies and serve as a primary choice when traditional methods fail, or when a less invasive approach is desired. The company’s established distribution channels and network of key opinion leaders for both Human and Animal Care in Europe, North America (only veterinary), Middle East, Asia, India, and Africa further enhance its ability to reach and impact a broad patient population.
(IQwave 3.0 CE for human is NOT US-FDA approved)
A Strong Team Leading the Way
Promoting employee engagement and satisfaction is also a priority for ChemoTech. The company fosters an environment of independent responsibility and ownership, encouraging entrepreneurship and boosting employee self-esteem. By valuing feedback and criticism as opportunities for improvement, ChemoTech continuously evolves and innovates, driving its business forward.
The Future of Health-Tech
Looking ahead, ChemoTech envisions a future where health technology is characterised by bionic thinking and minimal trauma. The company’s ongoing commitment to research and development will likely lead to the incorporation of new policies and practices aimed at further enhancing work culture and employee satisfaction. By continuously learning and adapting, ChemoTech aspires to make the world a better place to work and live.
ChemoTech’s future plans, include expanding its product portfolio to address effective pain management for cancer patients. With established distribution channels and a robust network of key opinion leaders, the company is well-positioned to continue its growth and impact in the global health-tech market.
Magazine 
